Whitfield Roy Ainsider trades

In SEC Form 4 filings, Whitfield Roy A is listed as Director of Nektar Therapeutics (NKTR). Whitfield Roy A reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 25.

Companies and roles

Company	Role	Transactions	Last filed
NKTRNektar Therapeutics	Director	2	Sep 25

Cluster buys

No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).

Form 4 historysince 2026-09-25

Company	Traded	Filed	Type	Shares	Price	Value	Owned after	10b5-1 plan	Filing
NKTRNektar Therapeutics	Sep 23	Sep 25	A	2,000	$0.00	$0	16,417	No	Form 4
NKTRNektar Therapeutics	Sep 23	Sep 25	A · derivative	4,000	$57.66	$230,640	4,000	No	Form 4

Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.